Educational Panel : Market Outlook—How Durable is the IPO Resurgence and M&A Slowdown?

Feb. 12, 2018: 5 p.m. - 5:55 p.m.
Salon 4

With more than 30 biotech IPOs in 2017 but M&A deal activity running at lower than average levels, the tension for CEOs is delivering a confident story of how to achieve profitable growth for investors while drug launches receive more scrutiny than ever.  As large biopharmas prune their portfolios and consider their repatriation options, the expectations run high for an uptick in M&A in 2018.  This session will include experienced deal makers and investors sharing their perspectives on where they see the promise of intensifying activity within the industry this year.


Moderator: Stephen B. Thau, Partner, Morrison & Foerster LLP


James Cappuccio, Managing Director, H.C. Wainwright and Co., LLC

Chris Garabedian, Chairman and CEO, Xontogeny

Stefan D. Loren, PhD, Managing Director, Healthcare Investment Banking, Oppenheimer & Co.

Michael Meyers, Head of Investment Banking, T. R. Winston & Company; Interim Chief Executive Officer, Tivorsan Pharmaceuticals, Inc.

Matthew Roden, PhD, Head of Strategic Corporate Development and Global BD Assessment, Bristol-Myers Squibb

Sapna Srivastava, PhD, Chief Financial Officer and Chief Strategy Officer, Abide Therapeutics


James Cappuccio
Managing Director

Chris Garabedian
Chairman and CEO

Stefan D. Loren, PhD
Managing Director, Hea...

Michael Meyers
Head of Investment Ban...

Matthew Roden, PhD
Head of Strategic Corp...

Sapna Srivastava, PhD
Chief Financial Office...

Stephen B. Thau